atrial fibrillation
Cardiovascular · 2010–2016
2decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| warfarin Prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism; prophylaxis and/or treatment of thromboembolic complications… | Nov 2016 | Not recommended | none received |
| dronedarone hydrochloride Treatment of patients with paroxysmal or persistent atrial fibrillation or flutter and at least one additional cardiovascular risk factor, in addition to… | Nov 2010 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.